-
1
-
-
41349099104
-
Cancer statistics, 2008
-
10.3322/CA.2007.0010
-
A Jemal R Siegel E Ward 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010
-
(2008)
CA Cancer J Clin
, vol.58
, Issue.2
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
3
-
-
7344242595
-
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)
-
10.1023/A:1008226721932
-
M Gershanovich HA Chaudri D Campos 1998 Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3) Ann Oncol 9 6 639 645 10.1023/A: 1008226721932
-
(1998)
Ann Oncol
, vol.9
, Issue.6
, pp. 639-645
-
-
Gershanovich, M.1
Chaudri, H.A.2
Campos, D.3
-
4
-
-
0031943424
-
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
-
P Dombernowsky I Smith G Falkson 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 2 453 461 (Pubitemid 28135586)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.2
, pp. 453-461
-
-
Dombernowsky, P.1
Smith, I.2
Falkson, G.3
Leonard, R.4
Panasci, L.5
Bellmunt, J.6
Bezwoda, W.7
Gardin, G.8
Gudgeon, A.9
Morgan, M.10
Fornasiero, A.11
Hoffmann, W.12
Michel, J.13
Hatschek, T.14
Tjabbes, T.15
Chaudri, H.A.16
Hornberger, U.17
Trunet, P.F.18
-
5
-
-
0034128928
-
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
-
M Kaufmann E Bajetta LY Dirix 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 7 1399 1411 (Pubitemid 30205385)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.7
, pp. 1399-1411
-
-
Kaufmann, M.1
Bajetta, E.2
Dirix, L.Y.3
Fein, L.E.4
Jones, S.E.5
Zilembo, N.6
Dugardyn, J.L.7
Nasurdi, C.8
Mennel, R.G.9
Cervek, J.10
Fowst, C.11
Polli, A.12
Di Salle, E.13
Arkhipov, A.14
Piscitelli, G.15
Miller, L.L.16
Massimini, G.17
-
6
-
-
0042848744
-
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results
-
10.1016/S0959-8049(03)00326-5
-
JM Nabholtz J Bonneterre A Buzdar JF Robertson B Thurlimann 2003 Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 12 1684 1689 10.1016/S0959-8049(03)00326-5
-
(2003)
Eur J Cancer
, vol.39
, Issue.12
, pp. 1684-1689
-
-
Nabholtz, J.M.1
Bonneterre, J.2
Buzdar, A.3
Robertson, J.F.4
Thurlimann, B.5
-
7
-
-
0038460245
-
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
-
10.1200/JCO.2003.04.194
-
H Mouridsen M Gershanovich Y Sun 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 11 2101 2109 10.1200/JCO.2003.04. 194
-
(2003)
J Clin Oncol
, vol.21
, Issue.11
, pp. 2101-2109
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
-
8
-
-
0035498544
-
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
-
10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
-
J Bonneterre A Buzdar JM Nabholtz 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 9 2247 2258 10.1002/1097-0142(20011101)92:9<2247::AID- CNCR1570>3.0.CO;2-Y
-
(2001)
Cancer
, vol.92
, Issue.9
, pp. 2247-2258
-
-
Bonneterre, J.1
Buzdar, A.2
Nabholtz, J.M.3
-
9
-
-
0034783960
-
Mechanisms of estrogen action
-
S Nilsson S Makela E Treuter 2001 Mechanisms of estrogen action Physiol Rev 81 4 1535 1565 (Pubitemid 32951806)
-
(2001)
Physiological Reviews
, vol.81
, Issue.4
, pp. 1535-1565
-
-
Nilsson, S.1
Makela, S.2
Treuter, E.3
Tujague, M.4
Thomsen, J.5
Andersson, G.6
Enmark, E.7
Pettersson, K.8
Warner, M.9
Gustafsson, J.-A.10
-
10
-
-
3543119043
-
Genomic targets of nuclear estrogen receptors
-
10.1210/me.2003-0044
-
R O'Lone MC Frith EK Karlsson U Hansen 2004 Genomic targets of nuclear estrogen receptors Mol Endocrinol 18 8 1859 1875 10.1210/me.2003-0044
-
(2004)
Mol Endocrinol
, vol.18
, Issue.8
, pp. 1859-1875
-
-
O'Lone, R.1
Frith, M.C.2
Karlsson, E.K.3
Hansen, U.4
-
11
-
-
0037224484
-
Nongenomic actions of steroid hormones
-
10.1038/nrm1009
-
R Losel M Wehling 2003 Nongenomic actions of steroid hormones Nature Rev Mol Cell Biol 4 1 46 56 10.1038/nrm1009
-
(2003)
Nature Rev Mol Cell Biol
, vol.4
, Issue.1
, pp. 46-56
-
-
Losel, R.1
Wehling, M.2
-
12
-
-
34548076290
-
Membrane-associated estrogen receptor signaling pathways in human cancers
-
10.1158/1078-0432.CCR-07-1373
-
RJ Pietras DC Marquez-Garban 2007 Membrane-associated estrogen receptor signaling pathways in human cancers Clin Cancer Res 13 16 4672 4676 10.1158/1078-0432.CCR-07-1373
-
(2007)
Clin Cancer Res
, vol.13
, Issue.16
, pp. 4672-4676
-
-
Pietras, R.J.1
Marquez-Garban, D.C.2
-
13
-
-
11144332004
-
Palmitoylation-dependent estrogen receptor alpha membrane localization: Regulation by 17beta-estradiol
-
10.1091/mbc.E04-07-0547
-
F Acconcia P Ascenzi A Bocedi 2005 Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol Mol Biol Cell 16 1 231 237 10.1091/mbc.E04-07-0547
-
(2005)
Mol Biol Cell
, vol.16
, Issue.1
, pp. 231-237
-
-
Acconcia, F.1
Ascenzi, P.2
Bocedi, A.3
-
14
-
-
18144381249
-
Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells
-
10.1016/j.steroids.2005.02.017
-
RJ Pietras DC Marquez HW Chen E Tsai O Weinberg M Fishbein 2005 Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells Steroids 70 5-7 372 381 10.1016/j.steroids.2005.02.017
-
(2005)
Steroids
, vol.70
, Issue.57
, pp. 372-381
-
-
Pietras, R.J.1
Marquez, D.C.2
Chen, H.W.3
Tsai, E.4
Weinberg, O.5
Fishbein, M.6
-
15
-
-
34547928773
-
A conserved mechanism for steroid receptor translocation to the plasma membrane
-
10.1074/jbc.M611877200
-
A Pedram M Razandi RC Sainson JK Kim CC Hughes ER Levin 2007 A conserved mechanism for steroid receptor translocation to the plasma membrane J Biol Chem 282 31 22278 22288 10.1074/jbc.M611877200
-
(2007)
J Biol Chem
, vol.282
, Issue.31
, pp. 22278-22288
-
-
Pedram, A.1
Razandi, M.2
Sainson, R.C.3
Kim, J.K.4
Hughes, C.C.5
Levin, E.R.6
-
16
-
-
32544454618
-
Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer
-
10.1016/j.mce.2005.11.020
-
DC Marquez HW Chen EM Curran WV Welshons RJ Pietras 2006 Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer Mol Cell Endocrinol 246 1-2 91 100 10.1016/j.mce.2005.11.020
-
(2006)
Mol Cell Endocrinol
, vol.246
, Issue.12
, pp. 91-100
-
-
Marquez, D.C.1
Chen, H.W.2
Curran, E.M.3
Welshons, W.V.4
Pietras, R.J.5
-
17
-
-
34247635503
-
Membrane-initiated steroid signaling action of estrogen and breast cancer
-
10.1055/s-2007-973431
-
RX Song 2007 Membrane-initiated steroid signaling action of estrogen and breast cancer Semin Reprod Med 25 3 187 197 10.1055/s-2007-973431
-
(2007)
Semin Reprod Med
, vol.25
, Issue.3
, pp. 187-197
-
-
Song, R.X.1
-
18
-
-
0028886694
-
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
-
10.1126/science.270.5241.1491
-
S Kato H Endoh Y Masuhiro 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 5241 1491 1494 10.1126/science.270.5241.1491
-
(1995)
Science
, vol.270
, Issue.5241
, pp. 1491-1494
-
-
Kato, S.1
Endoh, H.2
Masuhiro, Y.3
-
19
-
-
30944440262
-
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
-
DOI 10.1016/S0001-2092(06)60356-6
-
AM Byrne DJ Bouchier-Hayes JH Harmey 2005 Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med 9 4 777 794 10.1111/j.1582-4934.2005.tb00379.x (Pubitemid 43116546)
-
(2005)
Journal of Cellular and Molecular Medicine
, vol.9
, Issue.4
, pp. 777-794
-
-
Byrne, A.M.1
Bouchier-Hayes, D.J.2
Harmey, J.H.3
-
20
-
-
0032982818
-
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
-
10.1038/sj.bjc.6690196
-
SJ Houston TA Plunkett DM Barnes P Smith RD Rubens DW Miles 1999 Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer Br J Cancer 79 7-8 1220 1226 10.1038/sj.bjc.6690196
-
(1999)
Br J Cancer
, vol.79
, Issue.78
, pp. 1220-1226
-
-
Houston, S.J.1
Plunkett, T.A.2
Barnes, D.M.3
Smith, P.4
Rubens, R.D.5
Miles, D.W.6
-
21
-
-
0034667593
-
Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
-
10.1042/0264-6021:3510289
-
W Kolch 2000 Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions Biochem J 351 Pt 2 289 305 10.1042/0264-6021:3510289
-
(2000)
Biochem J
, vol.351
, Issue.PART 2
, pp. 289-305
-
-
Kolch, W.1
-
22
-
-
0024531977
-
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
-
S Nicholson JR Sainsbury P Halcrow P Chambers JR Farndon AL Harris 1989 Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer Lancet 1 8631 182 185 10.1016/S0140-6736(89)91202-6 (Pubitemid 19038803)
-
(1989)
Lancet
, vol.1
, Issue.8631
, pp. 182-185
-
-
Nicholson, S.1
Halcrow, P.2
Farndon, J.R.3
Sainsbury, J.R.C.4
Chambers, P.5
Harris, A.L.6
-
24
-
-
2942652871
-
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
-
J Shou S Massarweh CK Osborne 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 926 935 (Pubitemid 38868139)
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.12
, pp. 926-935
-
-
Shou, J.1
Massarweh, S.2
Osborne, C.K.3
Wakeling, A.E.4
Ali, S.5
Weiss, H.6
Schiff, R.7
-
25
-
-
15544391142
-
Angiogenesis of breast cancer
-
10.1200/JCO.2005.12.017
-
BP Schneider KD Miller 2005 Angiogenesis of breast cancer J Clin Oncol 23 8 1782 1790 10.1200/JCO.2005.12.017
-
(2005)
J Clin Oncol
, vol.23
, Issue.8
, pp. 1782-1790
-
-
Schneider, B.P.1
Miller, K.D.2
-
26
-
-
0026083903
-
Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
-
N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 1 8
-
(1991)
N Engl J Med
, vol.324
, Issue.1
, pp. 1-8
-
-
Weidner, N.1
Semple, J.P.2
Welch, W.R.3
Folkman, J.4
-
27
-
-
0035878753
-
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
-
JA Foekens HA Peters N Grebenchtchikov 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 14 5407 5414 (Pubitemid 32694919)
-
(2001)
Cancer Research
, vol.61
, Issue.14
, pp. 5407-5414
-
-
Foekens, J.A.1
Peters, H.A.2
Grebenchtchikov, N.3
Look, M.P.4
Meijer-Van Gelder, M.E.5
Geurts-Moespot, A.6
Van Der Kwast, T.H.7
Sweep, C.G.J.8
Klijn, J.G.M.9
-
28
-
-
0027751890
-
The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
-
JE Park GA Keller N Ferrara 1993 The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 12 1317 1326
-
(1993)
Mol Biol Cell
, vol.4
, Issue.12
, pp. 1317-1326
-
-
Park, J.E.1
Keller, G.A.2
Ferrara, N.3
-
29
-
-
34248191292
-
Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2
-
10.1007/s00262-006-0234-7
-
K Mimura K Kono A Takahashi Y Kawaguchi H Fujii 2007 Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2 Cancer Immunol Immunother 56 6 761 770 10.1007/s00262-006-0234- 7
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.6
, pp. 761-770
-
-
Mimura, K.1
Kono, K.2
Takahashi, A.3
Kawaguchi, Y.4
Fujii, H.5
-
30
-
-
0025688912
-
Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
-
10.1084/jem.172.6.1535
-
M Clauss M Gerlach H Gerlach 1990 Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration J Exp Med 172 6 1535 1545 10.1084/jem.172.6.1535
-
(1990)
J Exp Med
, vol.172
, Issue.6
, pp. 1535-1545
-
-
Clauss, M.1
Gerlach, M.2
Gerlach, H.3
-
31
-
-
0029867554
-
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
-
B Barleon S Sozzani D Zhou HA Weich A Mantovani D Marme 1996 Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood 87 8 3336 3343 (Pubitemid 26115364)
-
(1996)
Blood
, vol.87
, Issue.8
, pp. 3336-3343
-
-
Barleon, B.1
Sozzani, S.2
Zhou, D.3
Weich, H.A.4
Mantovani, A.5
Marme, D.6
-
32
-
-
0032515047
-
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation
-
10.1074/jbc.273.46.30336
-
HP Gerber A McMurtrey J Kowalski 1998 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation J Biol Chem 273 46 30336 30343 10.1074/jbc.273.46.30336
-
(1998)
J Biol Chem
, vol.273
, Issue.46
, pp. 30336-30343
-
-
Gerber, H.P.1
McMurtrey, A.2
Kowalski, J.3
-
33
-
-
0030734010
-
P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells
-
S Rousseau F Houle J Landry J Huot 1997 p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 15 18 2169 2177 10.1038/sj.onc.1201380 (Pubitemid 27493906)
-
(1997)
Oncogene
, vol.15
, Issue.18
, pp. 2169-2177
-
-
Rousseau, S.1
Houle, F.2
Landry, J.3
Huot, J.4
-
34
-
-
0035242371
-
VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase
-
10.1006/excr.2000.5102
-
JH Qi L Claesson-Welsh 2001 VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase Exp Cell Res 263 1 173 182 10.1006/excr.2000.5102
-
(2001)
Exp Cell Res
, vol.263
, Issue.1
, pp. 173-182
-
-
Qi, J.H.1
Claesson-Welsh, L.2
-
35
-
-
28744454292
-
Autocrine vascular endothelial growth factor signalling in breast cancer: Evidence from cell lines and primary breast cancer cultures in vitro
-
10.1007/s10456-005-9010-0
-
M Weigand P Hantel R Kreienberg J Waltenberger 2005 Autocrine vascular endothelial growth factor signalling in breast cancer: evidence from cell lines and primary breast cancer cultures in vitro Angiogenesis 8 3 197 204 10.1007/s10456-005-9010-0
-
(2005)
Angiogenesis
, vol.8
, Issue.3
, pp. 197-204
-
-
Weigand, M.1
Hantel, P.2
Kreienberg, R.3
Waltenberger, J.4
-
36
-
-
23044452790
-
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: Paracrine and autocrine effects
-
10.1210/en.2005-0103
-
Y Liang SM Hyder 2005 Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects Endocrinology 146 8 3632 3641 10.1210/en.2005-0103
-
(2005)
Endocrinology
, vol.146
, Issue.8
, pp. 3632-3641
-
-
Liang, Y.1
Hyder, S.M.2
-
37
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
-
10.1074/jbc.M010840200
-
RA Campbell P Bhat-Nakshatri NM Patel D Constantinidou S Ali H Nakshatri 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 13 9817 9824 10.1074/jbc.M010840200
-
(2001)
J Biol Chem
, vol.276
, Issue.13
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
38
-
-
66249139315
-
A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR +) metastatic breast cancer (MBC)
-
(May 20 suppl): abstr 1012
-
Cristofanilli M, Valero V, Mangalik A et al. (2008) A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR +) metastatic breast cancer (MBC). J Clin Oncol; 26(May 20 suppl): abstr 1012
-
(2008)
J Clin Oncol
, pp. 26
-
-
Cristofanilli, M.1
Valero, V.2
Mangalik, A.3
-
39
-
-
0033670240
-
Regulation of vascular endothelial growth factor expression by estrogens and progestins
-
10.2307/3454307
-
SM Hyder JC Huang Z Nawaz 2000 Regulation of vascular endothelial growth factor expression by estrogens and progestins Environ Health Perspect 108 5 785 790 10.2307/3454307
-
(2000)
Environ Health Perspect
, vol.108
, Issue.5
, pp. 785-790
-
-
Hyder, S.M.1
Huang, J.C.2
Nawaz, Z.3
-
40
-
-
0028815410
-
Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model
-
DE Morales KA McGowan DS Grant 1995 Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model Circulation 91 3 755 763
-
(1995)
Circulation
, vol.91
, Issue.3
, pp. 755-763
-
-
Morales, D.E.1
McGowan, K.A.2
Grant, D.S.3
-
41
-
-
0036051735
-
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer
-
10.1007/BF02967545
-
H Takei ES Lee VC Jordan 2002 In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer Breast Cancer 9 1 39 42 10.1007/BF02967545
-
(2002)
Breast Cancer
, vol.9
, Issue.1
, pp. 39-42
-
-
Takei, H.1
Lee, E.S.2
Jordan, V.C.3
-
42
-
-
0034086611
-
Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
-
SM Hyder Z Nawaz C Chiappetta GM Stancel 2000 Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor Cancer Res 60 12 3183 3190 (Pubitemid 30407915)
-
(2000)
Cancer Research
, vol.60
, Issue.12
, pp. 3183-3190
-
-
Hyder, S.M.1
Nawaz, Z.2
Chiappetta, C.3
Stancel, G.M.4
-
43
-
-
0033602501
-
Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
-
10.1016/S0303-7207(99)00003-9
-
JK Ruohola EM Valve MJ Karkkainen V Joukov K Alitalo PL Harkonen 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells Mol Cell Endocrinol 149 1-2 29 40 10.1016/S0303-7207(99)00003-9
-
(1999)
Mol Cell Endocrinol
, vol.149
, Issue.12
, pp. 29-40
-
-
Ruohola, J.K.1
Valve, E.M.2
Karkkainen, M.J.3
Joukov, V.4
Alitalo, K.5
Harkonen, P.L.6
-
44
-
-
33745925603
-
Estradiol increases VEGF in human breast studied by whole-tissue culture
-
10.1007/s00441-006-0159-7
-
S Garvin UW Nilsson FR Huss G Kratz C Dabrosin 2006 Estradiol increases VEGF in human breast studied by whole-tissue culture Cell Tissue Res 325 2 245 251 10.1007/s00441-006-0159-7
-
(2006)
Cell Tissue Res
, vol.325
, Issue.2
, pp. 245-251
-
-
Garvin, S.1
Nilsson, U.W.2
Huss, F.R.3
Kratz, G.4
Dabrosin, C.5
-
45
-
-
14944378653
-
Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells
-
JE Lee KW Chung W Han 2004 Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells Anticancer Res 24 6 3961 3964 (Pubitemid 40468693)
-
(2004)
Anticancer Research
, vol.24
, Issue.6
, pp. 3961-3964
-
-
Lee, J.E.1
Chung, K.-W.2
Han, W.3
Kim, S.-W.4
Kim, S.W.5
Shin, H.J.6
Bae, J.Y.7
Noh, D.-Y.8
-
46
-
-
23044463773
-
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
-
10.1200/JCO.2005.08.126
-
L Ryden K Jirstrom PO Bendahl 2005 Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer J Clin Oncol 23 21 4695 4704 10.1200/JCO.2005.08.126
-
(2005)
J Clin Oncol
, vol.23
, Issue.21
, pp. 4695-4704
-
-
Ryden, L.1
Jirstrom, K.2
Bendahl, P.O.3
-
47
-
-
2542561964
-
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
-
10.1056/NEJMoa032691
-
H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691
-
(2004)
N Engl J Med
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
48
-
-
33751094077
-
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones
-
10.1677/erc.1.01221
-
Y Liang RA Brekken SM Hyder 2006 Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones Endocr Relat Cancer 13 3 905 919 10.1677/erc.1.01221
-
(2006)
Endocr Relat Cancer
, vol.13
, Issue.3
, pp. 905-919
-
-
Liang, Y.1
Brekken, R.A.2
Hyder, S.M.3
-
49
-
-
13844296572
-
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up: Implication of a link between VEGF pathway and tamoxifen response
-
10.1007/s10549-004-1655-7
-
L Ryden M Stendahl H Jonsson S Emdin NO Bengtsson G Landberg 2005 Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up: implication of a link between VEGF pathway and tamoxifen response Breast Cancer Res Treat 89 2 135 143 10.1007/s10549-004-1655-7
-
(2005)
Breast Cancer Res Treat
, vol.89
, Issue.2
, pp. 135-143
-
-
Ryden, L.1
Stendahl, M.2
Jonsson, H.3
Emdin, S.4
Bengtsson, N.O.5
Landberg, G.6
-
50
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
10.1056/NEJMoa072113
-
K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676 10.1056/NEJMoa072113
-
(2007)
N Engl J Med
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
51
-
-
54249120945
-
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
-
(May 20 suppl) :abstr LBA1011
-
D. Miles D, Chan A, Romieu G et al. (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol; 26(May 20 suppl) :abstr LBA1011
-
(2008)
J Clin Oncol
, pp. 26
-
-
Miles D, D.1
Chan, A.2
Romieu, G.3
-
52
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
10.1200/JCO.2005.05.098
-
KD Miller LI Chap FA Holmes 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 792 799 10.1200/JCO.2005.05.098
-
(2005)
J Clin Oncol
, vol.23
, Issue.4
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
-
53
-
-
33748528270
-
Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
-
abstr 3050
-
Traina T, Rugo H, Caravelli J et al (2006) Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 24(18S):abstr 3050
-
(2006)
J Clin Oncol
, vol.24
-
-
Traina, T.1
Rugo, H.2
Caravelli, J.3
-
54
-
-
33947504730
-
Sunitinib: From rational design to clinical efficacy
-
10.1200/JCO.2006.06.3602
-
LQ Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 7 884 896 10.1200/JCO.2006.06.3602
-
(2007)
J Clin Oncol
, vol.25
, Issue.7
, pp. 884-896
-
-
Chow, L.Q.1
Eckhardt, S.G.2
-
55
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
10.1158/0008-5472.CAN-04-1443
-
SM Wilhelm C Carter L Tang 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 7099 7109 10.1158/0008-5472.CAN-04-1443
-
(2004)
Cancer Res
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
56
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
10.1200/JCO.2007.14.5375
-
HJ Burstein AD Elias HS Rugo 2008 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 11 1810 1816 10.1200/JCO.2007.14.5375
-
(2008)
J Clin Oncol
, vol.26
, Issue.11
, pp. 1810-1816
-
-
Burstein, H.J.1
Elias, A.D.2
Rugo, H.S.3
-
57
-
-
43549105235
-
Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer
-
Abstract 164
-
Bianchi G, Loibl S, Zamagni C et al. (2007) Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. ASCO Breast Cancer Symposium: Abstract 164
-
(2007)
ASCO Breast Cancer Symposium
-
-
Bianchi, G.1
Loibl, S.2
Zamagni, C.3
-
58
-
-
58149335533
-
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
-
10.1200/JCO.2007.15.5242
-
A Moreno-Aspitia RF Morton DW Hillman 2008 Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 J Clin Oncol 10.1200/JCO.2007.15.5242
-
(2008)
J Clin Oncol
-
-
Moreno-Aspitia, A.1
Morton, R.F.2
Hillman, D.W.3
-
59
-
-
67649451455
-
Sorafenib in hormone-receptor positive (ER/PR+) metastatic breast cancer (MBC) resistant to aromatase inhibitors (AIs)
-
Sept. 2008(Abstract 162)
-
Subramaniam DS, Wilkinson M, Liu M et al. (2008) Sorafenib in hormone-receptor positive (ER/PR+) metastatic breast cancer (MBC) resistant to aromatase inhibitors (AIs). ASCO Breast Cancer Symposium; Sept. 2008(Abstract 162)
-
(2008)
ASCO Breast Cancer Symposium
-
-
Subramaniam, D.S.1
Wilkinson, M.2
Liu, M.3
-
60
-
-
49249113484
-
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
-
10.1200/JCO.2007.10.8332
-
NS Azad EM Posadas VE Kwitkowski 2008 Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 22 3709 3714 10.1200/JCO.2007.10.8332
-
(2008)
J Clin Oncol
, vol.26
, Issue.22
, pp. 3709-3714
-
-
Azad, N.S.1
Posadas, E.M.2
Kwitkowski, V.E.3
-
61
-
-
67649448357
-
-
Microangiopathic Hemolytic Anemia (MAHA) in patients treated with Avastin® (bevacizumab) and sunitinib malate. FDA Medwatch 2008; posted July 14, 2008 http://www.fda.gov/medwatch/safety/2008/safety08. htm#Avastin(accessedAugust30,2008)
-
Microangiopathic Hemolytic Anemia (MAHA) in patients treated with Avastin® (bevacizumab) and sunitinib malate. FDA Medwatch 2008; posted July 14, 2008 http://www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin (accessed August 30, 2008)
-
-
-
|